NASDAQ:EIKN

Eikon Therapeutics Q3 2026 Earnings Results & Report

$4.83 -0.34 (-6.50%)
As of 02:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eikon Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$1.59 versus the -$1.74 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
6:30 AM ET

Eikon Therapeutics EPS Results

Actual EPS
-$1.59
Consensus EPS
-$1.74
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Eikon Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eikon Therapeutics Q3 2026 Earnings FAQ

Eikon Therapeutics (NASDAQ:EIKN) reported earnings of -$1.59 per share for Q3 2026, beating the consensus estimate of -$1.74. The report was announced on Thursday, November 12, 2026.

Eikon Therapeutics Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Eikon Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eikon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eikon Therapeutics and other key companies, straight to your email.

About Eikon Therapeutics

Eikon Therapeutics (NASDAQ:EIKN) is a biopharmaceutical company focused on discovering and developing medicines for serious diseases, including cancer. The company uses advanced imaging, computational biology and drug-discovery methods to study how proteins behave in living cells and identify potential therapeutic targets.

Founded in 2019 by Roger Perlmutter, a former head of Merck Research Laboratories, Eikon is based in California. Its work is centered on research and development; the company is not known for marketed medicines.

Eikon’s approach combines laboratory research with computational tools to guide the development of potential drug candidates. Its programs are aimed at advancing new treatments, particularly in oncology.

View Eikon Therapeutics Profile